BASF's Cash-Flow Bet Meets Wall Street Skepticism as Geismar Plant Starts Up

A fresh valuation model published today puts BASF's free cash flow recovery at the heart of the investment case, calculating a company value well above the current share price — but only if the chemicals group can deliver a lasting turnaround in cash generation. The gap between recent cash outflows and the inflows the optimistic scenario assumes is what makes the stock so sensitive to any disappointment on execution.

Two narratives, one gap

The bullish analyst narrative classifies BASF as undervalued, while the consensus view sees the shares as roughly fairly valued. The divergence comes down largely to expectations for future business performance. Underpinning the optimistic case are an annual savings target of EUR 2.3 billion by the end of 2026 and a reduction in core net fixed costs of up to 20% by 2029. The phasing matters: the near-term savings anchor and the longer-term overhaul of the cost base must together produce a durable improvement in earnings power and free cash flow.

Jefferies turns bearish

Not everyone is convinced. Jefferies downgraded BASF from "Hold" to "Underperform" today, keeping its price target at EUR 44. Analyst Priyanka Patel expects operating earnings for 2027 to come in 5% below consensus, citing higher gas prices, a lack of demand recovery, declining margins and persistent overcapacity. The shares were up 0.2% on the day.

Geismar comes online

Against that backdrop, BASF officially commissioned its new MDI production plant in Geismar, Louisiana, today. The investment totaled around USD 1 billion and lifts annual MDI capacity at the site to roughly 600,000 tonnes. CEO Markus Kamieth said the facility strengthens the core business and brings production closer to customers. The US business generated EUR 13.1 billion in sales in 2025, around 90% of it from locally manufactured products — an industrial base the new plant extends, provided BASF can utilize the additional capacity economically.

Evonik talks: no deal confirmed

Speculation about a possible takeover of Evonik remains just that. According to dpa-AFX, Evonik was still not conducting takeover negotiations with BASF on Monday; a meeting of the two companies' leadership was described as an informational exchange, with no confirmed progress on a deal.

Chile exit and a raised outlook

Elsewhere in the portfolio, ALTA Performance Materials signed a contract on Friday to acquire BASF's Palatal business in Chile. The group also raised its full-year guidance about two weeks ago and now expects EBITDA before special items of EUR 7.4 billion to EUR 7.8 billion for 2026.

For investors, the valuation question ultimately hinges on delivery: cost discipline and economic use of the expanded production would vindicate the optimistic model — if they translate into the sustainable cash inflows it assumes.